Keenan Brendan T, Ye Lichuan, Pien Grace W, Magalang Ulysses J, Benediktsdottir Bryndis, Gislason Thorarinn, Pack Allan I
Division of Sleep Medicine, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Bouvé College of Health Sciences School of Nursing, Northeastern University, Boston, MA, USA.
Sleep. 2025 Jul 11;48(7). doi: 10.1093/sleep/zsaf082.
As first described in Iceland over 10 years ago and since replicated across thousands of diverse subjects from community-based and clinical cohorts throughout the world, there exist different subtypes of obstructive sleep apnea (OSA) characterized by patient-reported symptoms. Subtypes defined by excessive sleepiness, disturbed sleep, and minimal symptoms have been consistently identified across these various cohorts and are often joined by a moderately sleepy subtype. Identifying symptom subtypes using cluster analysis provided a data-driven approach to formalize the concept of symptomatic differences among patients with OSA that has been discussed for decades in prior research and has important implications for future research and clinical applications. Current evidence favors excessive sleepiness as a marker of increased cardiovascular risk related to OSA, but there remains an opportunity for more research on non-cardiovascular endpoints. The framework of symptom subtypes can inform future randomized clinical trials, which are challenging in patients with excessive sleepiness, but both feasible and clinically important in the other subtypes. Symptom heterogeneity should also be used to move beyond a one-size-fits-all approach to treatment recommendations, including consideration of whether patients with minimally symptomatic OSA require or receive any benefits from therapy. Studies to identify the underlying mechanisms of different symptom presentations, demonstrate short-term reliability, determine the minimum number of questions required for accurate identification, and implement a tool for assigning subtypes in routine clinical practice are needed to realize the full potential of symptom subtypes to inform more personalized medicine approaches.
10多年前在冰岛首次被描述,此后在来自世界各地社区和临床队列的数千名不同受试者中得到验证,阻塞性睡眠呼吸暂停(OSA)存在以患者报告症状为特征的不同亚型。在这些不同队列中一直能识别出由过度嗜睡、睡眠紊乱和轻微症状定义的亚型,且常有一种中度嗜睡亚型。使用聚类分析识别症状亚型提供了一种数据驱动的方法,使OSA患者症状差异的概念形式化,这一概念在先前研究中已讨论数十年,对未来研究和临床应用具有重要意义。目前的证据支持将过度嗜睡作为与OSA相关的心血管风险增加的标志物,但在非心血管终点方面仍有更多研究机会。症状亚型框架可为未来的随机临床试验提供参考,这在过度嗜睡的患者中具有挑战性,但在其他亚型中既可行又具有临床重要性。症状异质性还应用于超越一刀切的治疗建议方法,包括考虑症状轻微的OSA患者是否需要治疗或能从治疗中获益。需要开展研究以确定不同症状表现的潜在机制、证明短期可靠性、确定准确识别所需的最少问题数量,并在常规临床实践中实施一种用于分配亚型的工具,以充分发挥症状亚型的潜力,为更个性化的医学方法提供依据。